Biotechnology

Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing

INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. Under this agreement, Samsung Biologics will provide a full scope of its ...

2020-10-19 19:00 1883

Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference

* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...

2020-10-16 20:00 12350

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further d...

2020-10-14 20:00 10627

Kanaph Therapeutics Closes 21M USD Series B Funding

SEOUL, South Korea, Oct. 12, 2020 /PRNewswire/ -- Kanaph Therapeutics, a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules, recently completed their Series B funding of21M USD in South Korea. In this round, a large Korean pharma company, GC Pharma...

2020-10-13 11:30 1093

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...

2020-10-12 08:30 6418

Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA

TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") announced today that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the ...

2020-10-09 06:39 1065

EB Research Partnership and EB Research Foundation Come Together as Largest Global Organization Advancing Research for Epidermolysis Bullosa

As the leading EB research funders worldwide, the group will combine to leverage EBRP's innovative business model to accelerate treatments and cures NEW YORK and MELBOURNE, Australia, Oct. 9, 2020 /PRNewswire/ -- EB Research Partnership (EBRP), based inNew York, and EB Research Foundation (EBRF) ...

2020-10-08 21:00 1943

Nagase R&D Center Increases Productivity of Rare Amino Acid "Ergothioneine" 1000-fold: Highest Production Efficiency Reported Using "Smart Cell" Technology

TOKYO, Oct. 7, 2020 /PRNewswire/ -- The Nagase R&D Center, the research and development arm of NAGASE & CO., LTD. based inTokyo, has been developing fermentative production technology for ergothioneine (EGT) (*1) and researching EGT's functions. Using revolutionary biotechnology developed as part...

2020-10-07 14:00 1385

CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

SHANGHAI, Oct. 5, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced thatthe United States (US) Food and Drug Administration (FDA) has granted orphan drug designation to one of CARsgen's first-in-class drug candidates, CT041, for the t...

2020-10-05 18:00 1523

Happiness Biotech Announced Receipt of FDA Registration For Its Hand Sanitizer

NANPING, China, Oct. 1, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company's hand sanitizer products have been registered with U.S. Food and Drug Administra...

2020-10-01 22:00 12209

TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand

TAIPEI, Sept. 30, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen")(Taiwan: 4157) today announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® ...

2020-09-30 15:51 823

ILIAS Biologics Closes $20.6 Million Series B Financing

DAEJEON, South Korea, Sept. 28, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a leading exosome-based therapeutics company, announced today that the Company has completed a Series B financing round of$20.6 million inSouth Korea. The initial investors from the Series A rou...

2020-09-28 19:00 982

World's first clinical trial of non-viral PD1 specific targeted CAR T therapy achieves great breakthroughs

SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- On September 25, 2020, BIORAY LABORATORIES Inc. ("Bioraylab"), a company specialized in gene therapy and cell drug R&D, announced for the first time that clinical trials of non-viral PD1 specific targeted CAR T therapy in relapsed/refractory B-cell non-Hod...

2020-09-28 19:00 996

Carmine Therapeutics named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020

CAMBRIDGE, Mass., Sept. 28, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has been named by FierceBiotech as one of 2020's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.  The 2020 Fierce 15 com...

2020-09-28 18:00 776

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA

NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...

2020-09-25 10:37 907

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has...

2020-09-24 17:12 942

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...

2020-09-24 00:09 1376

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...

2020-09-23 15:00 787

Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio

TOKYO, Sept. 22, 2020 /PRNewswire/ -- HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter:Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility ...

2020-09-23 09:00 1007

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...

2020-09-22 07:00 11482
12345 ... 106